Mount Sinai has teamed up with the Chiba Institute of Technology to integrate artificial intelligence (AI) into cardiovascular research, aiming to accelerate patient care and treatment innovations. This collaboration holds global significance in addressing cardiovascular disease challenges. Dr. Dennis Charney, Dean of Icahn Mount Sinai, highlights the synergy between technology and healthcare. They plan to conduct international clinical trials in AI, involving fields like interventional cardiology and cardiac imaging. The Chiba Institute’s expertise in AI, notably neurosymbolic AI, adds depth to the partnership. Customizing AI for healthcare, overcoming bias, and enhancing human roles in AI are wider industry trends.
Mount Sinai has joined forces with the Chiba Institute of Technology to revolutionize cardiovascular research through the integration of artificial intelligence. Dr. Dennis Charney, the Dean of Icahn Mount Sinai and President for Academic Affairs at Mount Sinai Health System expressed the significance of this collaboration, emphasizing its potential to bridge the gap between technology and healthcare.
The Icahn School of Medicine at Mount Sinai has officially entered into a memorandum of understanding with the Chiba Institute of Technology, with the primary objective of leveraging AI to enhance clinical trials for cardiovascular disease. Their shared goal is to advance patient care and expedite the development of innovative treatments for heart disease patients.
This partnership holds immense importance as it aims to pioneer novel strategies utilizing artificial intelligence in the prevention and treatment of cardiovascular disease, which is a pressing global health challenge. Dr. Deepak Bhatt, Director of Mount Sinai Heart and the Valentin Fuster Professor of Cardiovascular Medicine at Icahn Mount Sinai, envisions this joint initiative as a catalyst for creating a healthier world, emphasizing the critical nature of addressing cardiovascular diseases on a global scale.
The memorandum of understanding outlines plans to launch international clinical trials encompassing AI and various cardiovascular fields, such as interventional cardiology, cardiac electrophysiology, heart failure, cardiac imaging, and preventive cardiology. Researchers from the Chiba Institute of Technology will travel to Mount Sinai Heart in New York City to gain insights into the latest advancements in cardiovascular research, while Mount Sinai researchers will reciprocate by visiting Chiba, Japan, to acquire additional technological expertise.
It’s worth noting that Mount Sinai Heart has earned the prestigious distinction of being ranked No. 1 in New York and No. 4 globally among the 2024 World’s Best Specialized Hospitals by Newsweek.
Dr. Dennis Charney, the Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and President for Academic Affairs of the Mount Sinai Health System expressed eagerness about the collaboration, underscoring their commitment to advancing medical science in tandem with CIT.
The Chiba Institute of Technology, Japan’s oldest private technological university, is renowned for its dedication to innovation and a wide-ranging research portfolio encompassing fields like robotics and computer science. CIT’s mission is centered around delivering cutting-edge technological solutions to meet evolving societal needs.
CIT’s Center for Radical Transformation, established in 2021 and known as the Henkaku Center for Radical Transformation, is led by Joichi Ito, the president of CIT. The center is actively involved in the Probabilistic Computing Project, which focuses on developing neurosymbolic generative AI systems and supporting the use of InferenceQL, an open-source language for querying probabilistic programs modeling tabular data.
Neurosymbolic AI refers to the integration of neural network-based methods with symbolic knowledge-based approaches, a concept elucidated by Amit Sheth, the founding director of the Artificial Intelligence Institute at the University of South Carolina. This approach aims to create transparent and interpretable AI systems, particularly in safety-critical applications.
In the broader context, the responsible deployment of AI in healthcare, including addressing bias complexities, is seen as a stepwise process crucial for building trust in healthcare AI. While many healthcare organizations are embracing AI and analytics, there’s a growing emphasis on customizing AI models to fit specific organizational data and needs, according to Rich Birhanzel, Accenture’s healthcare lead.
This partnership between Mount Sinai and CIT is seen as a momentous collaboration that promises pioneering advancements in cardiovascular research and tangible benefits for patients worldwide. Joichi Ito, the president of CIT, expressed confidence in the partnership’s potential to harness the power of computational sciences, pushing the boundaries of what can be achieved in healthcare. Dr. Deepak Bhatt also highlighted the transformative nature of this collaboration, emphasizing its capacity to unlock new possibilities in healthcare through computational sciences.
